SCHEMBL4719992

SCHEMBL4719992

NCCCc1nc2ncccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.53
CYP2C9 P11712 1/20 0.51
NOS1 P29475 1/20 0.51
NOS2 P35228 1/20 0.51
HCAR2 Q8TDS4 4/20 0.45
POLB P06746 1/20 0.45
METAP1 P53582 2/20 0.44
METAP2 P50579 1/20 0.44
DRD4 P21917 1/20 0.43
TP53 P04637 2/20 0.42
DAGLA Q9Y4D2 1/20 0.42
HPGD P15428 2/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
RAB9A P51151 1/20 0.42
BACE1 P56817 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PDE5A O76074 4/20 0.41
PDE4A P27815 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8326986 0.84 NOS1 (0.54) NUDT1CYP2C9NOS1NOS2HCAR2
SCHEMBL4773954 0.83 NUDT1 (0.59) NUDT1CYP2C9NOS1NOS2POLB
SCHEMBL246326 0.83 PDE5A (0.53) NUDT1CYP2C9NOS1NOS2HCAR2
SCHEMBL3960231 0.80 CYP2C9 (0.57) NUDT1CYP2C9NOS1NOS2METAP1
SCHEMBL9597011 0.80 CYP2C9 (0.53) NUDT1CYP2C9NOS1NOS2POLB
SCHEMBL9570423 0.80 CYP2C9 (0.53) NUDT1CYP2C9NOS1NOS2HCAR2
SCHEMBL24823966 0.80 NUDT1 (0.45) NUDT1CYP2C9NOS1NOS2METAP1
SCHEMBL7002580 0.79 NUDT1 (0.58) NUDT1CYP2C9NOS1NOS2POLB
SCHEMBL8325044 0.79 DAGLA (0.53) NUDT1CYP2C9NOS1NOS2HCAR2
SCHEMBL21101319 0.78 CXCR4 (0.48) NUDT1CYP2C9NOS1NOS2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed